Nanoparticles (mRNA/siRNA/DNA)

Nanoparticles (mRNA/siRNA/DNA) — Program Design to GMP

Dual hubs: San Diego, CA (Southern California) & Montréal, Canada
Scope: Lipid nanoparticles (LNPs) for mRNA, siRNA, and plasmid DNA, with selective use of hybrid/polymeric systems where data justify. We cover formulation design, microfluidic mixing scale-up, solvent removal and buffer exchange, sterile filtration feasibility or aseptic processing, stability, fill–finish, and submission-ready documentation—all in a unified digital QMS (ALCOA+).

Nanoparticle programs succeed when physics, biochemistry, and documentation line up from the start. We begin by defining exactly what the patient must receive (dose, size window, encapsulation, osmolality, potency, sterility), then we build the process and analytical stack that proves those attributes lot after lot. The methods are practical, the ranges are operator-holdable, and the records read cleanly in inspection. The result is a modality that scales without improvisation.

Why teams choose MycoVista for nucleic-acid nanoparticles

A strong nanoparticle program is not a collection of clever experiments; it is a controlled system. We approach it with an established tone: state the constraints, select the simplest workable design, and measure the attributes that actually govern risk.

  • End-to-end execution. Payload readiness → formulation design → microfluidic mixing → TFF (solvent removal, buffer exchange) → filtration feasibility or aseptic isolators → fill–finish → stability. Two synchronized facilities, one way of working.
  • Prioritization of first principles. We tune FRR/TFR, N/P, temperature, pH/ionic strength, and TFF conditions to hold size, PDI, encapsulation, and potency. Every range is backed by data.
  • Orthogonal analytics where they reduce risk. Size/PDI paired with nucleic-acid integrity and dsRNA (for mRNA), residual solvents, osmolality, sterility, and potency—planned before development begins.
  • Operator-holdable processes. We avoid narrow, fragile settings. If a parameter can’t be held by trained staff on a night shift, it isn’t locked.

Background: constraints that actually govern modality success

The same avoidable issues appear across programs: (1) uncontrolled assembly at scale causing size drift and Enc% loss, (2) solvent removal performed under shear/temperature conditions that seed instability, (3) sterile filtration considered too late, and (4) analytics that are insufficiently orthogonal to catch drift. We address each constraint up front. We match energy density at scale, we instrument TFF for transmembrane pressure and shear, we test filtration feasibility early, and we specify acceptance criteria before any DoE.

Program spine: QTPP → CQAs → CPPs

QTPP (intended product): route (IM/IV/SC), dose per container, particle size window and PDI, Enc% lower bound, osmolality/pH range, potency target at release and over shelf life, sterility/endotoxin, and presentation (vial or PFS).
CQAs (measured attributes): hydrodynamic diameter and PDI, encapsulation efficiency, nucleic-acid integrity (and dsRNA for mRNA), residual solvent, pH/osmolality, sterile filter recovery (if applicable), potency, endotoxin, sterility; for DNA, topology (SC/OC/L) when relevant to function.
CPPs (controlled levers): FRR/TFR, N/P ratio, solvent fraction and temperature at mixing, quench/dilution chemistry, TFF TMP and cross-flow, diafiltration volume, hold temperatures and durations, filtration ∆P/T, and final buffer composition.

We codify the control strategy in protocols and batch records from day one.

Platform selection (keep it as simple as possible—and no simpler)

LNPs remain the first-line platform for mRNA/siRNA and many DNA uses. Composition (ionizable + helper + structural + PEG) is tuned to route and dose. We consider hybrid or polymeric systems only when stability or potency clearly improve and the validation footprint remains practical. Excipients earn inclusion; we avoid ornamental complexity.

Payload-specific notes

  • mRNA. We align formulation to cap structure, UTRs, length, and purity. dsRNA control is part of the plan, not a footnote.
  • siRNA. Thermodynamic asymmetry and guide-strand loading drive potency; we verify knockdown in phase-appropriate cell systems and tune composition for the intended route.
  • DNA (including pDNA). Size and topology affect Enc% and filtration feasibility; where DNA serves as the active payload, we design buffers and processing steps that preserve function and allow clean sterility claims.

Formulation design (payload first, then chemistry)

Pre-formulation. We confirm nucleic-acid integrity (and dsRNA for mRNA), define acceptable osmolality/pH, and screen buffer systems that allow controlled self-assembly while preserving downstream feasibility.

Mixing strategy. We use microfluidic devices with tuned FRR and TFR to control nucleation and growth. We maintain temperature profiles that stabilize assembly and solvent exchange. Before we scale, we demonstrate scale similarity by matching residence time and energy density.

TFF and solvent removal. We choose membranes and recipes that protect Enc% while clearing solvent and exchanging into the clinical buffer. We instrument shear and TMP; diafiltration volumes are set by measurement, not convention.

Sterile filtration feasibility. We test recovery and integrity on real bulk early. If filtration undermines potency or Enc%, we run aseptic isolators with validated media fills and robust EM performance.

Fill–finish. We set line settings (speed, nozzle, nitrogen overlay if needed) and verify container-closure integrity. For PFS, we manage silicone oil and glide-force realities. We validate holds and shipping lanes that reflect actual site logistics.

Analytics that answer the real questions

Physical: size and PDI (e.g., DLS or equivalent), zeta where informative, osmolality, pH, and visible/subvisible particulates where route demands.

Chemical/biochemical: Enc% (validated fluorometric or equivalent), nucleic-acid integrity (and dsRNA for mRNA), topology for DNA, residual solvent (phase-appropriate), and surfactant/excipient residuals if used.

Microbiological: sterility, endotoxin; for aseptic operations, EM trends are part of the batch record story.

Potency: cell-based or biochemical readouts tied to mechanism—translation/expression for mRNA, knockdown for siRNA, function for DNA payloads as applicable.

Lifecycle: method development → transfer (dual hubs) → qualification/validation. We plan orthogonality where it materially reduces risk and we predeclare OOS/OOT handling.

Route-specific considerations (IM, IV, SC)

IM. We control particle size for local reactogenicity and potency; osmolality and buffer strength are set for comfort and device compatibility.
IV. We prioritize filtration feasibility, osmolality, and buffer chemistries that preserve potency without over-stressing filters; particulate limits and inspection sensitivity are aligned to route.
SC. We manage viscosity and injection forces; for PFS we verify recovery across filters and device components.

In all cases, we base choices on data rather than platform folklore.

Stability programs (design for logistics that actually exist)

We design real and accelerated conditions that match distribution. Stress studies (heat, agitation, freeze–thaw, light) map failure modes so formulation can be targeted. For mRNA, dsRNA and potency retention hold the pen. For DNA, we monitor topology stability alongside Enc%. Shelf-life assignments are data-backed; any lane or component change triggers targeted comparability.

Validation, PPQ, and lifecycle files

Design space → recipe. Development ranges appear as setpoints, limits, and alarms in batch records.
Media fills. Aseptic simulations include interventions and holds representative of production; we trend outcomes over time.
Cleaning validation & E/L. Where contact surfaces and solvents justify, we run extractables/leachables and cleaning validation with defensible MACO/PDE logic.
Hold-time studies. We validate bulk and intermediate holds to avoid improvised practices on the line.

Facilities & scale

Production: development through production-relevant runs on microfluidic platforms; closed-system capability for sensitive steps.
Purification: recipe-controlled TFF with instrumentation (TMP, cross-flow, temperature), staged filtration trains, and integrity testing embedded in batch records.
DP: vial and PFS lines in isolators/RABS; CCIT platforms; visual inspection (manual/automated) with defined AQL.
Suites & utilities: ISO 8/7 with unidirectional flows; BSL-2 where required; HPW/clean steam/compressed air validated and trended.
Digital systems: validated CDS/LIMS/ELN and eBMR/eBR—one backbone across both hubs.

Regulatory and QMS posture

We write CMC sections that match practice: control strategy, process description, method files, validation summaries, media fill records, CCIT outcomes, and stability. We maintain deviation/CAPA and change-control histories that explain themselves. For site, scale, or material changes, we use prespecified comparability with acceptance windows and orthogonal confirmations where they reduce reviewer doubt.

Program Onboarding (first 30 days)

  1. Control strategy draft mapping QTPP → CQAs → CPPs for the intended route and payload, with proposed acceptance criteria.
  2. DoE plan for mixing and TFF (ranges, sampling, pass/fail) plus an analytical validation roadmap and, where relevant, a filtration feasibility plan.
  3. Gantt & risk register with decision gates to IND/registration; a stability plan matched to the shipping reality; and (for DNA payloads) a topology control plan.

We request current data (payload characteristics, early size/Enc%, residuals, any stability), then return a written plan with explicit gates.

Indicative timelines (biology- and physics-gated)

  • Feasibility (2–6 weeks). Payload integrity and dsRNA/topology baselines; initial mixing screens; Enc% and size/PDI on target; early solvent removal and filtration feasibility.
  • Development (2–4 months). DoE to lock FRR/TFR/N/P, temperature, TFF recipe; filtration feasibility confirmed; draft formulation and stability plan; analytics stack qualified.
  • Engineering runs. Scale-similar mixing/TFF with mass balance and trending; hold-time studies; aseptic readiness (if applicable).
  • Lock. Process description, CPP ranges, method files with qualification/validation plans, stability enrollment, and submission text.

We state gates and pass criteria; physics and payload determine pace.

Tech transfer and remediation

When programs arrive mid-stream, we stabilize first.

  • Triage. Methods, deviations, stability, change controls; mixing/TFF settings; filtration recovery; EM trends if aseptic.
  • Gap map. Which CQAs lack controls; which CPPs drift; quickest safe fixes (mixing energy, TFF shear, filtration parameters, buffer composition).
  • Stabilize → optimize → re-lock. Interim setpoints to stop failures; targeted DoE on the drivers; comparability where changes are made; lifecycle files updated.

Deliverables

  • Control strategy and process description with CPP ranges.
  • Formulation dossier (composition, mixing, TFF, filtration feasibility).
  • Analytics package (methods; transfer; qualification/validation; trending, including dsRNA or topology where relevant).
  • Stability protocol/data with defendable shelf-life rationale.
  • DP files (filling settings, inspection and CCIT plans, lane validations).
  • Batch records (eBMR/eBR) and CMC text ready for submission.

Frequently asked

Can you design LNPs to pass sterile filtration? Often, yes. We design to a size window and composition that filter cleanly. If filtration harms function, we use validated aseptic operations.
How do you control dsRNA for mRNA programs? We detect it, set acceptance criteria, and tune mixing/TFF so we don’t create it. The data sit in the file.
Do you support DNA payloads? Yes. We manage topology and Enc%, confirm filtration feasibility, and set buffers that preserve function.
What assures lot-to-lot equivalence across hubs? Mirrored methods, predefined transfer protocols with equivalence metrics, shared reference standards, and trending visible to QA in both sites.

Summary

This modality demands controlled assembly, measured removal, and practical analytics. We implement all three with ranges that operators can hold and records that read clearly in inspection. If you want a concrete plan for your payload and route, send current data and we’ll return a design space, acceptance criteria, and a documented path to GMP.

MycoVista | San Diego, CA & Montréal, Canada
Start Program Onboarding → Share payload class, route, dose goals, size window, and presentation. We’ll return a design space, control strategy, and a documented path to GMP.

EN / FR support available.